We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Read MoreHide Full Article
Key Takeaways
Solventum raised 2026 adjusted EPS guidance to $7.10-$7.20 and organic sales growth to 2.5%-3%.
SOLV targets about $500M in annual cost savings, with most benefits expected in 2027 and beyond.
Solventum ended Q2 with $4.57B in long-term debt, limiting flexibility as transformation spending continues.
Solventum Corporation (SOLV - Free Report) is showing better underlying growth, a higher earnings outlook and progress on cost reduction. Those trends improve the operating case after a period dominated by separation work.
The decision is less straightforward for investors. Temporary enterprise resource planning (ERP)-related advance orders and tariff refunds boosted second-quarter results, while a sizable debt load and a possible 2027 raw-material cost increase could restrain financial flexibility and future margin gains.
SOLV's Growth Drivers Strengthen
Normalized organic growth was about 4% in the second quarter after adjusting for ERP advance orders and stock-keeping unit (SKU) exits. Advanced Wound Care grew 7.1% organically, Acera advanced 48% year over year and Health Information Systems organic growth reached 5.4%.
Innovation adds another layer. Solventum expects almost 20 product launches through the first quarter of 2028, including Advanced Wound Care products in the first half of 2027. Medtronic plc (MDT - Free Report) , a global healthcare technology company, is also investing in new surgical technologies, keeping innovation execution important across the sector.
Image Source: Zacks Investment Research
Solventum's Cost Program Could Lift Margins
Transform for the Future targets about $500 million in annual cost savings through operating efficiencies, procurement, supply-chain changes, system streamlining and automation. Most benefits are expected in 2027 and beyond, giving Solventum a potential path to better margins as the program scales.
The separation from former parent 3M Company (MMM - Free Report) is also moving forward. Solventum had exited nearly 70% of roughly 200 transition service agreements and migrated about 950 of 1,200 systems by the second quarter, with separation costs expected to decline beginning in the fourth quarter.
SOLV's Debt Load Limits Flexibility
The balance sheet remains the clearest constraint. Solventum ended the second quarter with $403 million in cash and cash equivalents, compared with $506 million of short-term borrowings and the current portion of long-term debt. Long-term debt was $4.57 billion.
Management reported net debt of $4.7 billion and continues to emphasize debt reduction within its capital plan. Even with improving operating performance, the debt burden reduces room for error while Solventum funds transformation work, separation activities, acquisitions and shareholder returns.
Solventum's 2026 Outlook Has Caveats
Solventum raised adjusted earnings guidance to $7.10-$7.20 per share and lifted its organic sales growth range to 2.5%-3%. Excluding an expected 100-basis-point drag from SKU exits, organic growth is projected to be in the range of 3.5%-4%.
The quality of that outlook still matters. About $125 million of second-quarter sales came from ERP advance orders, with most of the benefit expected to reverse in the third quarter. Tariff refunds also aided margins, while a 2027 3M raw-material pricing option could create a 100-basis-point margin headwind if exercised.
Image Source: Zacks Investment Research
SOLV's Style Scores Support a Balanced View
The operating trend is improving, but the stock does not present a clear buy case yet. Growth drivers and cost actions are moving in the right direction, while debt, temporary second-quarter benefits and unresolved raw-material pricing risk argue for patience.
SOLV currently carries a Zacks Rank #4 (Sell). Its Value Score of B and VGM Score of B are favorable, while its Growth Score of C and Momentum Score of C are more neutral. Because Style Scores complement rather than override the Zacks Rank, the current combination supports a wait-and-see stance despite improving fundamentals.
View the Zacks #1 Rank List
Image: Bigstock
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Key Takeaways
Solventum Corporation (SOLV - Free Report) is showing better underlying growth, a higher earnings outlook and progress on cost reduction. Those trends improve the operating case after a period dominated by separation work.
The decision is less straightforward for investors. Temporary enterprise resource planning (ERP)-related advance orders and tariff refunds boosted second-quarter results, while a sizable debt load and a possible 2027 raw-material cost increase could restrain financial flexibility and future margin gains.
SOLV's Growth Drivers Strengthen
Normalized organic growth was about 4% in the second quarter after adjusting for ERP advance orders and stock-keeping unit (SKU) exits. Advanced Wound Care grew 7.1% organically, Acera advanced 48% year over year and Health Information Systems organic growth reached 5.4%.
Innovation adds another layer. Solventum expects almost 20 product launches through the first quarter of 2028, including Advanced Wound Care products in the first half of 2027. Medtronic plc (MDT - Free Report) , a global healthcare technology company, is also investing in new surgical technologies, keeping innovation execution important across the sector.
Image Source: Zacks Investment Research
Solventum's Cost Program Could Lift Margins
Transform for the Future targets about $500 million in annual cost savings through operating efficiencies, procurement, supply-chain changes, system streamlining and automation. Most benefits are expected in 2027 and beyond, giving Solventum a potential path to better margins as the program scales.
The separation from former parent 3M Company (MMM - Free Report) is also moving forward. Solventum had exited nearly 70% of roughly 200 transition service agreements and migrated about 950 of 1,200 systems by the second quarter, with separation costs expected to decline beginning in the fourth quarter.
SOLV's Debt Load Limits Flexibility
The balance sheet remains the clearest constraint. Solventum ended the second quarter with $403 million in cash and cash equivalents, compared with $506 million of short-term borrowings and the current portion of long-term debt. Long-term debt was $4.57 billion.
Management reported net debt of $4.7 billion and continues to emphasize debt reduction within its capital plan. Even with improving operating performance, the debt burden reduces room for error while Solventum funds transformation work, separation activities, acquisitions and shareholder returns.
Solventum's 2026 Outlook Has Caveats
Solventum raised adjusted earnings guidance to $7.10-$7.20 per share and lifted its organic sales growth range to 2.5%-3%. Excluding an expected 100-basis-point drag from SKU exits, organic growth is projected to be in the range of 3.5%-4%.
The quality of that outlook still matters. About $125 million of second-quarter sales came from ERP advance orders, with most of the benefit expected to reverse in the third quarter. Tariff refunds also aided margins, while a 2027 3M raw-material pricing option could create a 100-basis-point margin headwind if exercised.
Image Source: Zacks Investment Research
SOLV's Style Scores Support a Balanced View
The operating trend is improving, but the stock does not present a clear buy case yet. Growth drivers and cost actions are moving in the right direction, while debt, temporary second-quarter benefits and unresolved raw-material pricing risk argue for patience.
SOLV currently carries a Zacks Rank #4 (Sell). Its Value Score of B and VGM Score of B are favorable, while its Growth Score of C and Momentum Score of C are more neutral. Because Style Scores complement rather than override the Zacks Rank, the current combination supports a wait-and-see stance despite improving fundamentals.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.